ASSESSMENT OF ADHERENCE TO TREATMENT AND FACTORS AFFECTING IT IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE DURING THERAPY WITH NICORANDIL
https://doi.org/10.20996/1819-6446-2017-13-6-776-786
Abstract
Working Group of the NIKEA Program. Ekaterinburg: Akulina E.N.; Izhevsk: Shinkareva S. E., Grebnev S.A.; Krasnodar: Kudryashov E.A., Fendrikova A.V.; Krasnoyarsk: Nemik D.B., Pitaev R.R., Altaev V.D., Samokhvalov E.V., Stolbikov Y.Y.; Moscow: Dmitrieva N.A., Zagrebelnyy A.D., Zakharova A.V., Balashov I.S., Leonov A.S., Sladkova T.A., Zelenova T.I., Shestakova G.N., Kolganova E.V., Maksimova M.A.; Novosibirsk: Moskalenko I.V., Shurkevich A.A.; Omsk: Loginova E.N., Gudilin V.A.; Orel: Zhuravleva L.L., Lobanova G.N., Luneva M.M.; Orenburg: Kondratenko V.Y.; Rostov-on-Don: Kalacheva N.M., Kolomatskaia O.E., Dubishcheva N.F., Romadina G.V., Chugunova I.B., Skarzhinskaia N.S.; Ryazan: Bulanov A.V., Trofimova Y.M., Nikolaeva A.S.; St. Petersburg: Savinova E.B., Ievskaia E.V., Vasileva L.B.; Tula: Zubareva L.A., Berberfish L.D., Gorina G.I., Nadezhkina K.N., Iunusova K.N., Nikitina V.F., Dabizha V.G., Renko I.E., Soin I.A.
Aim. To study the adherence to treatment and the factors that affect it in patients with stable coronary heart disease during the treatment with nicorandil. Material and methods. The use of nicorandil in addition to standard antianginal therapy was recommended to patients (n=590) in a prospective, observational, multicenter NIKEA study. Patients completed original questionnaires on adherence, including a Morisky-Green test at the enroll visit. The questionnaires were filled by 423 patients (73% response). The factors that influence adherence were studied.
Results. All patients were divided into 3 groups, depending on the adherence to the use of nicorandil: immediately refused to take the drug (n=150; group 1); started, but stopped taking nicorandil in the first 3 months of observation (n=75; group 2); who took nicorandil for 3 months (n=327; group 3). Potentially adherents (intention to treat) were 582 out of 590 (98.6%) patients, and actually adherents – only 327 of 552 (59.2%) patients. The main reason for non-adherence to the beginning of therapy is polypharmacy; to the continuation of the treatment that had just started – adverse events; for termination of long-term therapy – polypharmacy, adverse events and insufficient effectiveness of treatment. Group 3 had initially more severe angina pectoris: more number of angina attacks (p=0.014) and the need of short-acting nitrates (p<0.0001). Patients of the group 1 compared to the patients of group 3 did not visit the doctors more often or attended them only when necessary, violated the medical prescriptions for taking medications (p<0.05). According to the results of the Morisky-Green test, 150 patients (36.2%) were not are committed to medical recommendations, 264 (63.8%) – are committed. Women were more adherent than men (p=0.47); patients with class I angina were more adherent than patients with class III angina (p=0.027), and patients who regularly attended the treating physician (more often than once a month) were more committed to medical recommendations than patients, not visiting the treating physician (p=0.004).
Сonclusion. The levels of overall adherence according to Morisky-Green test, the potential adherence according to the survey and the actual adherence of patients to treatment vary considerably. The leading cause of non-adherence at the beginning of therapy is polypharmacy, for the continuation of the recently started treatment – the adverse events; for long-term sustained treatment – equally polypharmacy, drug adverse events and the lack of treatment efficacy.
About the Authors
S. Yu. MartsevichRussian Federation
Sergey Yu. Martsevich – MD, PhD, Professor, Head of Department of Preventive Pharmacotherapy
Petroverigsky per. 10, Moscow, 101990
Yu. V. Lukina
Russian Federation
Yulia V. Lukina – MD, PhD, Leading Researcher, Department of Preventive Pharmacotherapy
Petroverigsky per. 10, Moscow, 101990
N. P. Kutishenko
Russian Federation
Natalia P. Kutishenko – MD, PhD, Professor, Head of Laboratory for Pharmacoepidemiological Studies, Department of Preventive Pharmacotherapy
Petroverigsky per. 10, Moscow, 101990
A. V. Akimova
Russian Federation
Anna V. Akimova – MD, Junior Researcher, Laboratory for Pharmacoepidemiological Studies, Department of Preventive Pharmacotherapy
Petroverigsky per. 10, Moscow, 101990
V. P. Voronina
Russian Federation
Viktoria P. Voronina – MD, PhD, Senior Researcher, Department of Preventive Pharmacotherapy
Petroverigsky per. 10, Moscow, 101990
O. V. Lerman
Russian Federation
Olga V. Lerman – MD, PhD, Senior Researcher, Department of Preventive Pharmacotherapy
Petroverigsky per. 10, Moscow, 101990
O. V. Gaisenok
Russian Federation
Oleg V. Gaisenok – MD, PhD, Head of Department of General Cardiology
Michurinskiy prosp. 6, Moscow, 119285
T. A. Gomova
Russian Federation
Tatyana A. Gomova – MD, PhD, Deputy Chief Physician on General Issues
Yablochkova ul. 1а, Tula, 300053
A. V. Ezhov
Russian Federation
Andrey V. Ezhov – MD, PhD, Professor, Chair of General Practitioner and Internal Medicine with the Course of Emergency Medical Care
Kommunarov ul. 281, Izhevsk, Republic of Udmurtia, 426034
A. D. Kuimov
Russian Federation
Andrey D. Kuimov – MD, PhD, Professor, Head of Chair of Faculty Therapy
Krasnii pr. 52, Novosibirsk, 630091
R. A. Libis
Russian Federation
Roman A. Libis – MD, PhD, Professor, Head of Chair of Hospital Therapy
Sovetskaya ul. 6, Orenburg, 460000
G. V. Matyushin
Russian Federation
Gennady V. Matyushin – MD, PhD, Professor, Head of Chair of Cardiology and Functional Diagnostics
Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022
T. N. Mitroshina
Russian Federation
Tatyana N. Mitroshina – MD, Cardiologist
Komsomolskaya ul. 32, Orel, 302001
G. I. Nechaeva
Russian Federation
Galina I. Nechaeva – MD, PhD, Professor, Head of Chair of Internal Medicine and Family Medicine
Lenina ul. 12, Omsk, 644099
I. I. Reznik
Russian Federation
Inna I. Reznik – MD, PhD, Professor, Chair of Therapy, Faculty of Advanced Studies and Postgraduate Training of Doctors
Repina ul. 3, Ekaterinburg, 620014
V. V. Skibitsky
Russian Federation
Vitaliy V. Skibitsky – MD, PhD, Professor, Head of Chair of Hospital Therapy
Mitrofana Sedina ul. 4, Krasnodar, 350063
L. A. Sokolova
Russian Federation
Lyudmila A. Sokolova – MD, PhD, Professor, Leading Researcher, Research Laboratory of Preventive Cardiology
Akkuratova ul. 2, St. Petersburg, 197341
A. I. Chesnikova
Russian Federation
Anna I. Chesnikova – MD, PhD, Professor, Chair of Internal Medicine №1
Suvorova ul. 119, Rostov-on-Don, 344022
N. V. Dobrynina
Russian Federation
Natalia V. Dobrynina – MD, PhD, Assistant, Chair of Hospital Therapy
Visokovoltnaya ul. 9, Ryazan, 390026
S. S. Yakushin
Russian Federation
Sergey S. Yakushin – MD, PhD, Professor, Head of Chair of Hospital Therapy
Visokovoltnaya ul. 9, Ryazan, 390026
References
1. Lukina Yu.V., Kutishenko N.P., Martsevich S.Yu. Treatment adherence: modern view on a well known issue. Cardiovascular Therapy and Prevention. 2017;16(1):91-5. (In Russ.) [Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю. Приверженность лечению: современный взгляд на знакомую проблему. Кардиоваскулярная Терапия и Профилактика. 2017;16(1):91-5. doi: 10.15829/1728-88002017-1-91-95
2. World Health Organization. Adherence to long-term therapies: evidence for action.WHO Library Cataloguing-in-Publication Data, Geneva: WHO; 2003.
3. Phillips L.S., Branch W.T.Jr., Cook C.B., et al. Clinical inertia. Ann Intern Med. 2001;135: 825-34. doi: 10.7326/0003-4819-135-9-200111060-00012.
4. Minakov E.V., Khokhlov R.A., Furmenko G.I., Akhmedzhanov N.M. Doctor inertness as a factor disturbing effective treatment of cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2009;5(2):39-48. (In Russ.) [Минаков Э.В., Хохлов Р.А., Фурменко Г.И., Ахмеджанов Н.М. Клиническая инертность как фактор, препятствующий эффективному лечению сердечно-сосудистых заболеваний. Рациональная Фармакотерапия в Кардиологии. 2009;5(2):39-48. doi:10.20996/1819-6446-2009-5-2-39-48
5. Martsevich S.Yu, Lukina Yu.V., Kutishenko N.P., et al. Obsevational multisenter trial of nicorandil use in stable coronary heart disease high risk patients (NIKEA): desine and first Results. Russian Journal of Cardiology. 2017;(9):75-82. (In Russ.) [Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П., и др. Наблюдательное многоцентровое исследование применения никорандила у больных стабильной ишемической болезнью сердца с высоким сердечно-сосудистым риском (НИКЕЯ): дизайн, первые Результаты. Российский Кардиологический Журнал. 2017;(9):75-82]. doi: 10.15829/15604071-2017-9-75-82
6. Lukina Yu.V., Ginzburg M.L., Smirnov V.P. et al. Treatment compliance in patients with acute coronary syndrome before hospitalization. Clinician. 2012;(2): 41-9. (In Russ.) [Лукина Ю.В., Гинзбург М.Л., Смирнов В.П. и др. Приверженность лечению, предшествующему госпитализации, у пациентов с острым коронарным синдромом. Клиницист. 2012;2:41-9].
7. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34(38):2949-3003. doi: 10.1093/eurheartj/eht296.
8. Lukina Yu.V., Kutishenko N.P., Dmitrieva N.A., Martsevich S.Yu. Compliance to clinician prescriptions in ischemic heart disease patients (by the data from outpatient registry PROFILE). Russian Journal of Cardiology. 2017;3(143):14-9. (In Russ.) [Лукина Ю.В., Кутишенко Н.П., Дмитриева Н.А., Марцевич С.Ю. Приверженность больных хронической ишемической болезнью сердца к врачебным рекомендациям (по данным амбулаторного регисра ПРОФИЛЬ). Российский Кардиологический Журнал. 2017;3(143):14-9].
9. Semenova Y.V., Kutishenko N.P., Martsevich S.Y. Analysis of the problem of low adherence of patients to attendance at outpatient clinics and cardiorehabilitation programs according to the data from published studies. Rational Pharmacotherapy in Cardiology. 2015;11(6):618-25. (In Russ.) [Семенова Ю.В., Кутишенко Н.П., Марцевич С.Ю. Анализ проблемы низкой приверженности пациентов к посещению амбулаторных учреждений и программ кардиореабилитации по данным опубликованных исследований. Рациональная Фармакотерапия в Кардиологии. 2015;11(6):618-25]. doi:10.20996/1819-6446-2015-11-6-618-625
10. Morisky D.E., Ang A., Krousel-Wood M., Ward H.J. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348-54. doi: 10.1111/j.1751-7176.2008.07572.x.
11. Sontakke S., Budania R., Bajait C. et al. Evaluation of adherence to therapy in patients of chronic kidney disease. Indian J Pharmacol. 2015;47(6):668-71. doi: 10.4103/0253-7613.169597.
12. Nguyen T.M.U, Caze A.L., Cottrell N. Validated adherence scales used in a measurement-guided medication management approach to target and tailor a medication adherence intervention: a randomised controlled trial. BMJ Open. 2016;6(11):e013375. doi:10.1136/bmjopen-2016-013375.
13. Semenova O.N., Naumova E.A. Factors influencing adherence to therapy: WHO parameters and the opinion of patients in the cardiology department. Bulletin of medical Internet conferences. 2013;3(3):507-11. (In Russ.) [Семенова О.Н., Наумова Е.А. Факторы, влияющие на приверженность к терапии: параметры ВОЗ и мнение пациентов кардиологического отделения. Бюллетень медицинских Интернет‐конференций. 2013;3(3):507-11].
14. Garner J.B. Problems of nonadherence in cardiology and proposals to improve outcomes. Am J Cardiol.
Review
For citations:
Martsevich S.Yu., Lukina Yu.V., Kutishenko N.P., Akimova A.V., Voronina V.P., Lerman O.V., Gaisenok O.V., Gomova T.A., Ezhov A.V., Kuimov A.D., Libis R.A., Matyushin G.V., Mitroshina T.N., Nechaeva G.I., Reznik I.I., Skibitsky V.V., Sokolova L.A., Chesnikova A.I., Dobrynina N.V., Yakushin S.S. ASSESSMENT OF ADHERENCE TO TREATMENT AND FACTORS AFFECTING IT IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE DURING THERAPY WITH NICORANDIL. Rational Pharmacotherapy in Cardiology. 2017;13(6):776-786. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-6-776-786